Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Weighted Average): 2015-2025

Historic Shares Outstanding (Weighted Average) for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $9.9 million.

  • Aytu Biopharma's Shares Outstanding (Weighted Average) rose 61.20% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 61.20%. This contributed to the annual value of $6.2 million for FY2025, which is 10.81% up from last year.
  • Per Aytu Biopharma's latest filing, its Shares Outstanding (Weighted Average) stood at $9.9 million for Q3 2025, which was up 60.64% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Shares Outstanding (Weighted Average) peaked at $9.9 million during Q3 2025, and registered a low of $894,145 during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $5.6 million (2024), whereas its average is $5.7 million.
  • Data for Aytu Biopharma's Shares Outstanding (Weighted Average) shows a peak YoY surged of 676.91% (in 2021) over the last 5 years.
  • Aytu Biopharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $1.4 million in 2021, then surged by 121.79% to $3.1 million in 2022, then spiked by 78.36% to $5.6 million in 2023, then rose by 10.45% to $6.1 million in 2024, then surged by 61.20% to $9.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $9.9 million in Q3 2025, compared to $6.2 million in Q2 2025 and $6.2 million in Q1 2025.